Person:
Kohli, Puja

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Kohli

First Name

Puja

Name

Kohli, Puja

Filters

2016 - 201912020 - 20211

Settings

Author's Publications: search.filters.isAuthorOfPublication.86f5de9e-d580-4eac-9dad-60f46413e634

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
    (Springer Science and Business Media LLC, 2021-06) Zekavat, Seyedeh M.; Lin, Shu-Hong; Bick, Alexander G.; Liu, Aoxing; Paruchuri, Kaavya; Wang, Chen; Uddin, Md Mesbah; Ye, Yixuan; Yu, Zhaolong; Liu, Xiaoxi; Kamatani, Yoichiro; Bhattacharya, Romit; Pirruccello, James; Pampana, Akhil; Loh, Po-Ru; Kohli, Puja; McCarroll, Steven; Kiryluk, Krzysztof; Neale, Benjamin; Ionita-Laza, Iuliana; Engels, Eric; Brown, Derek W.; Smoller, Jordan; Green, Robert; Karlson, Elizabeth; Lebo, Matthew; Ellinor, Patrick; Weiss, Scott; Daly, Mark; Terao, Chikashi; Zhao, Hongyu; Ebert, Benjamin; Reilly, Muredach; Ganna, Andrea; Machiela, Mitchell; Genovese, Giulio; Natarajan, Pradeep
    The burden of mosaic chromosomal alterations in blood-derived DNA, a type of clonal hematopoiesis, is associated with an increased risk for diverse types of infections, including sepsis and pneumonia. Age is the dominant risk factor for infectious diseases, but the mechanisms linking age to infectious disease risk are incompletely understood. Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA, are structural somatic variants indicative of clonal hematopoiesis, and are associated with aberrant leukocyte cell counts, hematological malignancy, and mortality. Here, we show that mCAs predispose to diverse types of infections. We analyzed mCAs from 768,762 individuals without hematological cancer at the time of DNA acquisition across five biobanks. Expanded autosomal mCAs were associated with diverse incident infections (hazard ratio (HR) 1.25; 95% confidence interval (CI) = 1.15-1.36; P = 1.8 x 10(-7)), including sepsis (HR 2.68; 95% CI = 2.25-3.19; P = 3.1 x 10(-28)), pneumonia (HR 1.76; 95% CI = 1.53-2.03; P = 2.3 x 10(-15)), digestive system infections (HR 1.51; 95% CI = 1.32-1.73; P = 2.2 x 10(-9)) and genitourinary infections (HR 1.25; 95% CI = 1.11-1.41; P = 3.7 x 10(-4)). A genome-wide association study of expanded mCAs identified 63 loci, which were enriched at transcriptional regulatory sites for immune cells. These results suggest that mCAs are a marker of impaired immunity and confer increased predisposition to infections.
  • No Thumbnail Available
    Publication
    Lung Hyperinflation and Cardiac Impairment in Chronic Obstructive Pulmonary Disease
    (2016-05-18) Kohli, Puja; Harris, Robert S.; Celli, Bartolome; Dougherty, Darin D.; Cho, Josalyn
    Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide. Significantly, COPD carries a 2-5 fold increased risk of cardiovascular disease (CVD). This association persists even after accounting for shared risk factors, such as tobacco smoking. However, few studies have evaluated distinct pathophysiological mechanisms contributing to poor cardiovascular outcomes in individuals with COPD and CVD. Our hypothesis is that lung hyperinflation from COPD influences this cardiopulmonary relationship. In support of this hypothesis, studies of lung volume reduction surgery have suggested improvement in cardiovascular performance after surgical deflation. However, the mediators of this relationship are still generally unclear and essentially unknown in patients with both COPD and CVD. Given the frequent co-morbidity of COPD and CVD, an understanding of this complex relationship is critical to: 1) identifying COPD patients at risk for poor cardiovascular outcomes and 2) developing novel treatments to address this additional CVD risk in COPD patients. The purpose of this project is to identify structural, hemodynamic, and functional cardiac alterations unique to subjects with hyperinflation from a population of individuals with both COPD and CVD. We hypothesize that amongst individuals with COPD and CVD, lung hyperinflation leads to decreased cardiac chamber sizes, diminished cardiac filling, and, consequently, reduced cardiac output which can be reversed with lung deflation strategies. We will first investigate these questions using a local cohort of 8,000 subjects who have undergone cardiac MRIs, the current gold standard for cardiac chamber quantification, and analyze CMR- derived measures of cardiac structure and function in subjects with COPD and CVD, with and without hyperinflation. To understand the relationship of cardiac geometry to cardiac physiology, we will analyze previously ascertained invasive hemodynamic parameters from right heart catheterization, the gold standard for such measurements, in the same subjects. To help discern causal effects, we will use a novel reversible, non-invasive lung deflation device prospectively on ten subjects with hyperinflation and evaluate the hemodynamic effects of acute deflation with non-invasive impedance cardiography.